[1] Siegel RL, Miller KD, Jemal A,et al.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30. [2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132. [3] Chuong MD, Hallemeier CL, Jabbour SK, et al. Improving outcomes for esophageal cancer using proton beam therapy[J].Int J Radiat Oncol Biol Phys,2016,95(1):488-497. [4] 中国非手术治疗食管癌的临床分期小组.非手术治疗食管癌的临床分期标准(草案)[J].中华放射肿瘤学杂志,2010,19(3):179-180. [5] 殷蔚伯,余子豪,徐国镇主编.肿瘤放射治疗学(第四版)[M].北京:中国协和医科大学出版社,2008:561-562. [6] Higuchi K, Komori S, Tanabe S, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil(DCF-R) in advanced esophageal cancer: a phase 2 trial(KDOG 0501-P2)[J].Int J Radiat Oncol Biol Phys,2014,89(4):872-879. [7] Obnuma H, Sato Y, Hirakawa M, et al. A Phase 1/2 study of definitive chemoradiation therapy using docetaxel, nedaplatin, and 5-fluorouracil (DCF-R) for esophageal cancer [J].Int J Radiat Oncol Biol Phys,2015,93(2):382-390. [8] 董辉,祝淑钗,苏景伟,等.食管癌根治性放疗中ENI与IFI失败模式研究[J].中华放射肿瘤学杂志,2014,23(6):479-483. [9] 祝淑钗,尤鑫,李曙光, 等.食管癌三维适形调强放疗不同靶区照射局部失败的剂量学比较[J].中华放射医学与防护杂志,2015,35(11):830-834. [10] Maja N.Christiansen,Jenny Chik,Ling Lee,et al.Cell surface protein glycosylation in cancer[J].Proteomics,2014,14(4-5):525-546. [11] Saeland E,Belo AI,Mongera S,et al. Differential glycosylation of MUCI and CEACAM5 between normal mucosa and tumour of colon cancer patients[J].Int J Cancer,2012,131(1):117-128. [12] 孙兴权,李静,耿美玉,等.乳腺癌相关糖复合物糖链研究进展[J].中国药理学通报,2007,23(4):425-427. [13] 曹奎杰,刘燕婕.卵巢上皮癌患者ABO血型抗原表达异常与血清糖链蛋白水平的关系[J].中华检验学杂志.2010,33(3):267-268. [14] 金韩,展红光,崔熙.肿瘤异常蛋白检测系统对消化系统肿瘤检测效力的评价[J].现代医学,2006,8(34):270-271. [15] 李红云, 祝淑钗,苏景伟,等.食管癌根治性放化疗长期生存影响因素分析[J].中华放射肿瘤学杂志,2016,25(11):1177-1181. (本文编辑:詹道友) [收稿日期] 2017-10-30